AVEO:NSD-AVEO Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 4.00

Change

0.00 (0.00)%

Market Cap

USD 0.14B

Volume

0.23M

Avg Analyst Target

USD 18.00 (+350.00%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


AVEO Pharmaceuticals Inc (AVEO) Stock Analysis:
Based on the AVEO Pharmaceuticals Inc stock forecasts from 1 analysts, the average analyst target price for AVEO Pharmaceuticals Inc is USD 18.00 over the next 12 months. AVEO Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of AVEO Pharmaceuticals Inc is Slightly Bearish, which is based on 4 positive signals and 6 negative signals. At the last closing, AVEO Pharmaceuticals Inc’s stock price was USD 4.00. AVEO Pharmaceuticals Inc’s stock price has changed by -7.19% over the past week, -30.92% over the past month and -40.74% over the last year.

About

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-15 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals Inc

N/A

USD70.91B 8.97 6.88
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD63.10B 27.38 17.74
MRNA Moderna Inc

N/A

USD54.86B 4.87 2.41
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

N/A

USD38.40B 3.79 1.55
RPRX Royalty Pharma plc

N/A

USD26.93B 26.81 14.86
SGEN Seagen Inc

N/A

USD24.97B 55.02 44.86
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
GMAB Genmab A/S

N/A

USD18.31B 43.41 4.62
ARGX argenx SE

N/A

USD16.90B N/A N/A

ETFs Containing AVEO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -14.71% 86% B 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -14.71% 86% B 57% F
Trailing 12 Months  
Capital Gain -40.74% 74% C 37% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -40.74% 74% C 36% F
Trailing 5 Years  
Capital Gain 534.92% 95% A 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 534.92% 95% A 96% A
Average Annual (5 Year Horizon)  
Capital Gain 169.56% 94% A 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 169.56% 94% A 96% A
Risk Return Profile  
Volatility (Standard Deviation) 359.46% 7% F 4% F
Risk Adjusted Return 47.17% 85% B 75% C
Market Capitalization 0.14B 54% F 33% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 84.80 10% F 11% F
Price/Book Ratio 3.33 23% F 24% F
Price / Cash Flow Ratio -2.41 49% F 63% D
EV/EBITDA 48.85 5% F 12% F
Management Effectiveness  
Return on Equity -131.44% 20% F 10% F
Return on Invested Capital -74.58% 33% F 14% F
Return on Assets -35.96% 28% F 9% F
Debt to Equity Ratio 82.76% 23% F 25% F
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 5.20 48% F 31% F
Short Percent 3.76% 58% F 42% F
Beta 1.16 58% F 45% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.